Physician profile
Brian R Wolf
NPI 1730640772
$2,224.68
in general payments reported to CMS, 2019-2025
21 companies · $2,199 in 2025
The $2,199 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $25.40 · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Education: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.74 |
| Education | $640.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $595.91 | 2025 | Datroway, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $300.60 | 2025 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $208.65 | 2025 | |
| Astellas Pharma US INC | $188.99 | 2025 | |
| Genmab U.S., INC. | $127.03 | 2024-2025 | Tivdak, Epkinly |
| Exelixis INC. | $125.00 | 2025 | Cabometyx |
| Eisai INC. | $97.19 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $76.80 | 2025 | Opdivo |
| Seagen INC. | $74.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.74 | 2025 | Ninlaro, Fruzaqla |
| Celgene Corporation | $52.74 | 2025 | Reblozyl |
| Syndax Pharmaceuticals, INC. | $49.37 | 2025 | Revuforj |
| Novartis Pharmaceuticals Corporation | $46.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.36 | 2025 | |
| Tactile Systems Technology INC | $28.32 | 2025 | Flexitouch Plus, Nimbl |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $27.55 | 2025 | Pyrukynd |
| Taiho Oncology, INC. | $25.32 | 2025 | |
| Pfizer INC. | $25.20 | 2025 | |
| Janssen Scientific Affairs, LLC | $23.75 | 2025 | Talvey |
| Lilly USA, LLC | $19.42 | 2025 | Verzenio |
| Servier Pharmaceuticals LLC | $18.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.